Evaluating the Evolving Real‐World Adverse Events of <scp>GLP</scp> ‐ <scp>1RAs</scp> Using <scp>FDA</scp> Adverse Event Reporting System ( <scp>FAERS</scp> )

GLP-1RAs are linked to a broad range of AEs across indications. These findings stress the need for careful clinical monitoring and long-term safety evaluation. This study also illustrates how real-world evidence can inform safety communications, as well as hypothesis generation for research on next-generation GLP-1RAs.